Study Finds Radium-223 Effective in Prostate Cancer Treatment Independently of Docetaxel Use

Study Finds Radium-223 Effective in Prostate Cancer Treatment Independently of Docetaxel Use
A recent study titled “Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial”, published in The Lancet Oncology journal, has concluded that radium-223 dichloride (Xofigo), a radiopharmaceutical drug for prostate

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *